SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (Nasdaq:NSTR) today reported that through December 31, 2006, the Company had randomized a total of 118 patients in its pivotal EVEREST clinical trial for recovery of hand and arm function following a stroke. Planned investments in EVEREST, its three other ongoing clinical trials, and enhancements to its cortical stimulation platform resulted in a net loss of $5.3 million and $25.1 million for the quarter and year ended December 31, 2006, compared to a net loss of $3.6 million and $14.6 million for the quarter and the year ended December 31, 2005, respectively. The Company also reported cash, cash equivalents and investments of $105.3 million at December 31, 2006 compared to $20.2 million at December 31, 2005.
